Related Experiment Videos
[Supranuclear progressive paralysis (or oculo-facial-cervical dystonia)].
Schweizer Archiv Fur Neurologie, Neurochirurgie Und Psychiatrie = Archives Suisses De Neurologie, Neurochirurgie Et De Psychiatrie
|January 1, 1975
Summary
This study confirms progressive supranuclear palsy (PSP) as a distinct neurological disease. Neuropathological findings reveal consistent brainstem and subcortical lesions, with no identified cause or effective L-Dopa treatment.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Context:
- Progressive supranuclear palsy (PSP) is a rare, idiopathic neurodegenerative disease.
- Understanding PSP's clinical and pathological characteristics is crucial for diagnosis and management.
Purpose:
- To describe clinical and neuropathological findings in 14 progressive supranuclear palsy cases.
- To confirm PSP's distinct nosological status among CNS degenerative diseases.
Summary:
- The study details 14 progressive supranuclear palsy cases, including neuropathological analysis in 8.
- Consistent clinical features included supranuclear ophthalmoplegia, pseudobulbar syndrome, axial dystonia, and subcortical dementia.
- Neuropathology showed homogeneous lesions primarily affecting brainstem reticular substance and cranial nerve nuclei.
- Disease duration averaged 4 years, with onset slightly later than literature averages; males were not predominantly affected.
- No etiology was identified, and L-Dopa treatment showed no efficacy.
Impact:
- Confirms progressive supranuclear palsy as a well-defined neurological entity.
- Highlights the characteristic neuropathological hallmarks of PSP.
- Underscores the lack of identified etiology and ineffective L-Dopa treatment, guiding future research and clinical practice.